Odonate Therapeutics (ODT) PT Raised to $11 at Goldman Sachs, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ODT Hot Sheet
Price: $1.12 --0%
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 9
Rating Summary:
0 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 11 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on Odonate Therapeutics (NASDAQ: ODT) to $11.00 (from $10.00) while maintaining a Sell rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ferrari NV (RACE:IM) (RACE) PT Lowered to EUR395 at BofA Securities
- Invincible Investment Corp (8963:JP) PT Lowered to JPY63,000 at CLSA
- Boeing (BA) PT Lowered to $240 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
